Short Bowel Syndrome clinical trials
12 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
- Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
- Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
- A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
- Fiber Food Introduction in Pediatric Short Bowel Syndrome
- A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
- Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure
- A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
- Successful Fiber Food Introduction in Short Bowel Syndrome
- Palliative Care Needs of Children With Rare Diseases and Their Families
- Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Short Bowel Syndrome” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.